Teva Reports Fourth Quarter and Full Year 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Teva Pharma (TEVA) PT Lowered to $20 at RBC Capital
February 14, 2019 6:50 AM ESTRBC Capital analyst Randall Stanicky lowered the price target on Teva Pharma (NYSE: TEVA) to $20.00 (from $22.00) while maintaining a Sector Perform rating.
... MoreTeva Pharma (TEVA) Misses Q4 EPS by 1c, FY Guidance Misses
February 13, 2019 7:01 AM ESTTeva Pharma (NYSE: TEVA) reported Q4 EPS of $0.53, $0.01 worse than the analyst estimate of $0.54. Revenue for the quarter came in at $4.6 billion versus the consensus estimate of $4.52 billion.
GUIDANCE:
Teva Pharma sees FY2019 EPS of $2.20-$2.50, versus the consensus... More
